DB:0LW

Stock Analysis Report

Executive Summary

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Neovacs's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0LW's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

0LW

5.1%

DE Biotechs

-2.7%

DE Market


1 Year Return

-83.9%

0LW

-10.6%

DE Biotechs

-20.4%

DE Market

Return vs Industry: 0LW underperformed the German Biotechs industry which returned 10.4% over the past year.

Return vs Market: 0LW underperformed the German Market which returned 16.5% over the past year.


Shareholder returns

0LWIndustryMarket
7 Day0%5.1%-2.7%
30 Day0%-5.4%-18.4%
90 Day0%-22.4%-26.7%
1 Year-83.9%-83.9%-10.4%-10.6%-18.1%-20.4%
3 Year-95.4%-95.4%16.0%14.8%-19.1%-25.9%
5 Year-96.6%-96.7%-6.3%-8.8%-19.5%-30.4%

Price Volatility Vs. Market

How volatile is Neovacs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Neovacs undervalued compared to its fair value and its price relative to the market?

1.67x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 0LW's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 0LW's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 0LW is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0LW is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0LW's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0LW is good value based on its PB Ratio (1.7x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Neovacs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

56.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neovacs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Neovacs performed over the past 5 years?

-11.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0LW is currently unprofitable.

Growing Profit Margin: 0LW is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0LW is unprofitable, and losses have increased over the past 5 years at a rate of -11.9% per year.

Accelerating Growth: Unable to compare 0LW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0LW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 0LW has a negative Return on Equity (-170.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is Neovacs's financial position?


Financial Position Analysis

Short Term Liabilities: 0LW's short term assets (€8.7M) exceed its short term liabilities (€4.3M).

Long Term Liabilities: 0LW's short term assets (€8.7M) exceed its long term liabilities (€70.4K).


Debt to Equity History and Analysis

Debt Level: 0LW's debt to equity ratio (1.3%) is considered satisfactory.

Reducing Debt: 0LW's debt to equity ratio has reduced from 45.3% to 1.3% over the past 5 years.


Balance Sheet

Inventory Level: 0LW has a low level of unsold assets or inventory.

Debt Coverage by Assets: 0LW's debt is covered by short term assets (assets are 135.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0LW has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 0LW has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.9% each year


Next Steps

Dividend

What is Neovacs's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 0LW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0LW's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0LW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0LW's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0LW's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.8yrs

Average board tenure


CEO

Vincent Serra

0.42

Tenure

Mr. Vincent Serra, Ph. D. serves as Chief Executive Officer at Neovacs S.A. since September 30, 2019. Mr. Serra served as Chief Scientific Officer at Neovacs S.A. since February 2019 until September 30, 20 ...


Board Members

NamePositionTenureCompensationOwnership
Daniel Zagury
Founderno data€13.00kno data
Arlene Morris
Independent Director8.75yrs€11.00kno data
Jean-Jacques Bertrand
Chairman10yrs€24.00kno data
Patrick Valroff
Independent Director8.75yrs€11.00kno data
Thomas Kündig
Member of Scientific Research Committeeno data€3.00kno data
Robert Gallo
Vice Chairman of Scientific Research Committeeno datano datano data
Arsène Burny
Member of Scientific Research Committeeno datano datano data
Armand Bensussan
Vice Chairman of Scientific Research Committeeno datano datano data
Jacques Banchereau
Chairman of Scientific Advisory Board & Directorno data€12.00kno data
Martine Bagot
Member of Scientific Research Committeeno datano datano data

8.8yrs

Average Tenure

75yo

Average Age

Experienced Board: 0LW's board of directors are considered experienced (8.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 50%.


Top Shareholders

Company Information

Neovacs S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Neovacs S.A.
  • Ticker: 0LW
  • Exchange: DB
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €8.307m
  • Shares outstanding: 143.22m
  • Website: https://www.neovacs.fr

Number of Employees


Location

  • Neovacs S.A.
  • 3-5, Impasse Reille
  • Paris
  • Ile-de-France
  • 75014
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALNEVENXTPA (Euronext Paris)YesCommon SharesFREURApr 2009
0LWDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2009
0W8ULSE (London Stock Exchange)YesCommon SharesGBEURApr 2009

Biography

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/09 18:48
End of Day Share Price2019/11/12 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.